Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Avoid Thermo Fisher Scientific Inc. (NYSE:TMO)?

Thermo Fisher Scientific Inc. (NYSE:TMO) has experienced a decrease in enthusiasm from smart money of late.

At the moment, there are tons of indicators market participants can use to analyze publicly traded companies. Some of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the top hedge fund managers can outclass the broader indices by a healthy margin (see just how much).

Thermo Fisher Scientific Inc.

Equally as beneficial, optimistic insider trading activity is another way to break down the world of equities. There are many incentives for a bullish insider to downsize shares of his or her company, but just one, very simple reason why they would behave bullishly. Plenty of empirical studies have demonstrated the market-beating potential of this method if investors know what to do (learn more here).

Now, let’s take a peek at the key action surrounding Thermo Fisher Scientific Inc. (NYSE:TMO).

What does the smart money think about Thermo Fisher Scientific Inc. (NYSE:TMO)?

Heading into 2013, a total of 40 of the hedge funds we track held long positions in this stock, a change of -13% from one quarter earlier. With the smart money’s sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were upping their stakes substantially.

Of the funds we track, Boykin Curry’s Eagle Capital Management had the most valuable position in Thermo Fisher Scientific Inc. (NYSE:TMO), worth close to $352 million billion, accounting for 2.5% of its total 13F portfolio. On Eagle Capital Management’s heels is Blue Ridge Capital, managed by John Griffin, which held a $320 million position; the fund has 4.4% of its 13F portfolio invested in the stock. Other hedgies that are bullish include Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital, Larry Robbins’s Glenview Capital and Phill Gross and Robert Atchinson’s Adage Capital Management.

Judging by the fact that Thermo Fisher Scientific Inc. (NYSE:TMO) has witnessed a declination in interest from hedge fund managers, it’s easy to see that there was a specific group of funds that decided to sell off their positions entirely at the end of the year. At the top of the heap, Robert Rodriguez and Steven Romick’s First Pacific Advisors LLC sold off the largest investment of the “upper crust” of funds we monitor, worth an estimated $216 million in stock.. Andreas Halvorsen’s fund, Viking Global, also said goodbye to its stock, about $112 million worth. These moves are intriguing to say the least, as total hedge fund interest was cut by 6 funds at the end of the year.

How have insiders been trading Thermo Fisher Scientific Inc. (NYSE:TMO)?

Bullish insider trading is particularly usable when the primary stock in question has experienced transactions within the past half-year. Over the latest half-year time period, Thermo Fisher Scientific Inc. (NYSE:TMO) has seen zero unique insiders purchasing, and 9 insider sales (see the details of insider trades here).

With the results demonstrated by Insider Monkey’s time-tested strategies, everyday investors should always monitor hedge fund and insider trading activity, and Thermo Fisher Scientific Inc. (NYSE:TMO) is an important part of this process.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!